We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Zentek Ltd - ZEN

10 Sep 2022 07:02 AM <--
09 Sep 2022 12:53 PM
17 Jun 2022 03:30 PM
20 Mar 2022 02:58 PM
09 Nov 2021 04:11 PM
09 Nov 2021 03:59 PM
09 Nov 2021 01:22 PM
27 Oct 2021 10:36 AM
30 Aug 2021 06:25 PM
30 Aug 2021 05:57 PM
07 Mar 2020 12:58 PM
07 Mar 2020 05:58 AM
07 Mar 2020 04:55 AM
09 Sep 2015 02:13 PM
15 May 2015 03:16 PM
12 May 2015 12:39 PM
12 May 2015 11:39 AM
12 May 2015 10:45 AM
12 May 2015 09:59 AM
02 Sep 2014 03:09 AM
12 Jan 2014 01:55 PM
07 Aug 2013 11:57 AM
07 Jul 2013 06:49 PM
03 Jul 2013 11:22 AM
25 May 2013 08:41 PM

Return to Zentek Ltd - ZEN
Zentek Improving lives through nanotechnology.

Zentek is an IP development and commercialization company that uses expertise in nanomaterials and strategic partnerships to break through the barriers of molecular science and uncover new possibilities in healthcare and beyond. We believe our proven, next-generation, patented nanotechnologies will help solve the world’s most complex challenges.

Next-gen defense to combat transmission and infection.

Our technology helps filter pathogens to reduce the risk of transmission in indoor spaces, higher risk work environments and with social interactions.

Advancing rapid detection and diagnostics.

Our cutting-edge nanotechnology offers fast, affordable, non-invasive, scalable point-of-care detection for numerous pathogens, including viruses like COVID-19, empowering governments, health agencies and individuals worldwide to identify infections and end outbreaks faster than ever before.

Enhancing recovery and health outcomes.

We are developing breakthrough antimicrobial therapies so people can recover faster and live their lives to the fullest. Testing to date has shown our nanotech-powered therapies are safe and effective against numerous pathogens and can potentially transform modalities in medicine across the globe.

In-vitro testing shows 99.9% effectiveness against bacteria, fungi and viruses at extremely low minimum inhibitory concentrations (MIC).

Zentek's patent-pending graphene-based formulation has achieved excellent safety results and has the potential to be a game changer for treating human-contracted pathogens and infectious disease management.


Investor Info: